Payment overview · 2025
General Payments
$2,776.54
147 reported records · 26 companies
Healthcare provider profile · identity verified
Andrew Willson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BAY CITY, MI · NPI 1952770976
Verified facts
What the public records show
CMS Open Payments records show Andrew Willson, PA-C received $2,776.54 in general payments during 2025 across 147 reported records.
ABBVIE INC. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $352.71 | 12.7% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $322.58 | 11.6% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $288.11 | 10.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $257.62 | 9.3% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $220.55 | 7.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $216.76 | 7.8% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $150.47 | 5.4% | 21 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $113.24 | 4.1% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $108.33 | 3.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.89 | 3.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.20 | 3.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $75.34 | 2.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.47 | 2.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $55.55 | 2.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.16 | 1.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.85 | 1.6% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $42.16 | 1.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.87 | 1.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $36.15 | 1.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.14 | 1.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.90 | 0.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.87 | 0.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.01 | 0.8% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $19.63 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.50 | 0.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.48 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,776.54 | 147 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $322.58 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $278.25 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $223.08 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $210.90 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $161.60 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $145.87 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $131.65 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $126.50 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $120.38 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $113.24 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $108.33 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $100.49 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $100.49 | 6 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $90.85 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.94 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $84.94 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $74.46 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.34 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.04 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.28 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.38 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.38 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $53.66 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.85 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $39.80 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.33 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.82 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Kyleena Normalized: kyleena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| Mirena Normalized: mirena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $9.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 36 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 258 | 76 |
| Lisinopril | Lisinopril | 124 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 34 |
| Metformin Hcl | Metformin Hcl | 100 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 92 | 29 |
| Gabapentin | Gabapentin | 74 | 23 |
| Losartan Potassium | Losartan Potassium | 74 | 23 |
| Simvastatin | Simvastatin | 73 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 21 |
| Omeprazole | Omeprazole | 67 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 35 |
| Furosemide | Furosemide | 58 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 23 |
| Potassium Chloride | Potassium Chloride | 46 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 11 |
| Allopurinol | Allopurinol | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 14 |
| Eliquis | Apixaban | 36 | 11 |
| Meloxicam | Meloxicam | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Methylprednisolone | Methylprednisolone | 35 | 33 |
| Sertraline Hcl | Sertraline Hcl | 34 | 11 |
| Prednisone | Prednisone | 33 | 25 |
| Tramadol Hcl | Tramadol Hcl | 30 | 13 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Alprazolam | Alprazolam | 22 | 15 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Atenolol | Atenolol | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,776.54 · 147 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, Azstarys, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DUROLANE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, HETLIOZ, INSPIRE, JARDIANCE, KISUNLA, Kerendia, Korlym, Kyleena, LEQVIO, M-M-R II, MOUNJARO, Mirena, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PROQUAD, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, Tymlos, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error